pamufetinib   Click here for help

GtoPdb Ligand ID: 10460

Synonyms: TAS-115 | TAS115
Compound class: Synthetic organic
Comment: Pamufetinib (TAS-115) is a dual MET/VEGFR2(KDR) receptor tyrosine kinase inhibitor [1]. It was designed by Taiho Pharmaceutical as a potential anticancer drug [2]. It is a Type 1 ATP competitive inhibitor.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 3
Rotatable bonds 11
Topological polar surface area 133.67
Molecular weight 518.14
XLogP 4.32
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES CNC(=O)c1cc2c(ccnc2cc1OC)Oc1ccc(cc1F)NC(=S)NC(=O)Cc1ccccc1
Isomeric SMILES CNC(=O)c1cc2c(ccnc2cc1OC)Oc1ccc(cc1F)NC(=S)NC(=O)Cc1ccccc1
InChI InChI=1S/C27H23FN4O4S/c1-29-26(34)19-14-18-21(15-24(19)35-2)30-11-10-22(18)36-23-9-8-17(13-20(23)28)31-27(37)32-25(33)12-16-6-4-3-5-7-16/h3-11,13-15H,12H2,1-2H3,(H,29,34)(H2,31,32,33,37)
Bioactivity Comments
Off-targets detected in a kinase screening panel include PDGFRα and -β, AXL, KIT, SRC, and FLT1 [1]. Overall TAS-115 exhibits improved selectivity compared to sunitinib.
Selectivity at catalytic receptors
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
kinase insert domain receptor Hs Inhibitor Inhibition 7.9 pKi - 1
pKi 7.9 (Ki 1.2x10-8 M) [1]
MET proto-oncogene, receptor tyrosine kinase Hs Inhibitor Inhibition 7.4 pKi - 1
pKi 7.4 (Ki 3.9x10-8 M) [1]